GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-09-07| Trending

HHS Strikes Deal With AmerisourceBergen for Expanded Monkeypox Treatment Distribution

by Max Heirich
Share To

On September 7, the U.S. Department of Health and Human Services (HHS) announced a significant expansion to their monkeypox vaccine distribution. The expansion results from a $19.8 million contract awarded to AmerisourceBergen. As a result, shipments of the JYNNEOS vaccine will increase to 2,500 per week. 

Related Article: Monkeypox Cases Fall In The UK But A New Strain Of The Disease Emerges

The Treatments Distributed for Monkeypox

The two monkeypox treatments affected by this contract are the JYNNEOS vaccine and the TPOXX antiviral.

Manufactured by Bavarian Nordic, JYNNEOS is a vaccine approved by the FDA for the prevention of monkeypox and smallpox. Originally approved in 2019, the vaccine is instrumental in the current monkeypox endemic, with over 800,000 vials shipped nationwide. 

However, due to ever-increasing demand, the FDA issued an Emergency Use Authorization for the method of vaccine administration in August. Rather than inject the vaccine beneath the skin (subcutaneously) in two doses, four weeks apart, medical professionals could now administer JYNNEOS one-fifth of a single dose between the layers of the skin (intradermally) for the same level of protection.

Developed by Siga Technologies, TPOXX is an antiviral for the treatment of smallpox. However, at the time of its approval, smallpox had been declared eradicated since 1980. Despite a lack of established safety and efficacy of TPOXX’s treatment of monkeypox, the Center for Disease Control (CDC) holds an Expanded Access Investigational New Drug protocol (EA-IND) that allows for its treatment of diseases outside of smallpox, including monkeypox.  

The contract announced today expanded federal monkeypox treatment distribution to communities at the greatest risk of monkeypox infections.

The Expanded Monkeypox Treatment Distribution Deal

The $19.8 million contract awarded to AmerisourceBergen, a drug wholesale company, expands the Strategic National Stockpile’s (SNS) distribution capability. Before the deal, the SNS shipped these products to approximately five locations per jurisdiction. The HHS estimates that once implemented, the shipments of frozen JYNNEOS vaccine will increase up to 2,500 per week. In addition, the deal opens shipments of TPOXX to 2,500 locations. 

On the contract, HHS Assistant Secretary Dawn O’Connell said, “Today’s announcement is the result of our real-time and ongoing conversations with states and jurisdictions aimed at improving the national response. This new commercial contract will help deliver vaccines and treatments to communities and at-risk individuals more quickly and bring us a step closer to ending the current outbreak.”

As of early September, the SNS distributed over 800,000 vials of JYNNEOS across the nation, in addition to 37,000 courses of TPOXX. With the contract announced today, that number will likely skyrocket, expanding the availability of treatments and protection against monkeypox.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
Trump Administration’s Halt on Federal Health Agency Communications Raises Alarming Transparency Risks
2025-01-25
Will U.S. ‘s HHS $590 Million Investment Spark a New Era in mRNA Vaccines for Pandemic Flu Threats?
2025-01-22
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top